Evidence map›Paper›PMID 40794154›Full record

ReviewVirus genes2025

Insights of HIV-1 and HBV transcriptional regulation by viral transactivator Tat and HBx.

Zhonglan Wu, Jianxin Pei, Yong Li

Abstract readReview
PubMed Publisher
In one paragraph

Review in Virus genes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Zhonglan Wu *College of Life Sciences, University of Ningxia, Wencui Street, Yinchuan, Ningxia, China.
Jianxin Pei *Ningxia Center for Disease Control and Prevention, 528, Shengli Street, Yinchuan, Ningxia, China.
Yong LiCollege of Life Sciences, University of Ningxia, Wencui Street, Yinchuan, Ningxia, China. liyong7732@nxu.edu.cn.

Funding

The 2024 National Public Health Leading Talents Program (No. 2024005), sponsored by the National Administration of Disease Control and Prevention. No. 2024005
6 · The paper itself

Abstract

Transcriptions of nascent HIV-1 RNA from the integrated proviral DNA, and HBV RNAs from a stably formed minichromosome of cccDNA, are carried out by cellular RNA polymerase II, and strongly regulated by viral transactivation proteins Tat and HBx, respectively. Both Tat and HBx are intrinsically disordered proteins with promiscuous gene transactivation activities and regulate HIV-1 and HBV transcription by multiple, but similar mechanisms. The antiviral therapies of HIV-1 and HBV effectively suppress viral replication and enable the infection into latent states. The viral life cycles of HIV-1 and HBV differ significantly, but the core mechanisms of T-cell depletion are intertwined. Consequently, future therapeutic interventions must encompass a dual strategy of viral clearance and immune reconstitution. A functional cure would be achieved by combining checkpoint inhibitors, specific T-cell activators, and drugs targeting viral persistence.

Indexed as

Gene Expression Regulation, ViralHepatitis B virusHIV-1tat Gene Products, Human Immunodeficiency VirusTrans-ActivatorsViral TranscriptionHepatitis BHIV InfectionsHumansTranscriptional ActivationViral Regulatory and Accessory ProteinsVirus Replicationhepatitis B virus X proteintat Gene Products, Human Immunodeficiency VirusTrans-ActivatorsViral Regulatory and Accessory ProteinsHBVHBxHIVTatTranscriptional-regulation

Identifiers

PMID40794154

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.